Genocea Appoints Girish Aakalu, Ph.D., Chief Business Officer
December 10 2018 - 7:00AM
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical
company developing personalized cancer immunotherapies, today
announced the hiring of industry veteran Girish Aakalu, Ph.D., as
its new Chief Business Officer. In this role, Dr. Aakalu will lead
the company’s business development efforts.
“With his track record of success and strategic acumen, Girsh is
a great addition to the Genocea leadership team,” said Chip Clark,
President & CEO of Genocea. “Business development continues to
play a key role in our plans for leadership in the cancer
immunotherapy field, and we believe that Girish will help us
maximize our pipeline opportunities and capitalize on the myriad of
possible applications of our ATLAS™ platform, which uses each
patient’s immune response machinery to identify and characterize
antigens, rather than relying on predictive approaches.”
Dr. Aakalu brings a broad skillset to Genocea, spanning business
development, corporate and R&D strategy, product portfolio
management, commercial planning, and alliance management, following
positions at the Ipsen Group, a global specialty biopharmaceutical
company, which included Vice President: Global Head of External
Innovation, and positions at Pfizer, Inc., which included Executive
Director: Head of Strategy, Innovation & Operations for
Pfizer’s External R&D Innovation team. His previous roles also
include business development and oncology pipeline market planning
positions at Genentech, Inc. and life science consulting experience
at L.E.K Consulting. He received a B.A. in Biophysics from Johns
Hopkins University and a Ph.D. in Cellular and Molecular
Neurobiology from the California Institute of Technology.
About Genocea Biosciences, Inc.Genocea's
mission is to help conquer cancer by designing and delivering
targeted cancer vaccines and immunotherapies. While traditional
immunotherapy discovery methods have largely used predictive
methods to propose T cell targets, or antigens, Genocea has
developed ATLAS™, its proprietary technology platform, to identify
clinically relevant antigens of T cells based on actual human
immune responses. Genocea is currently studying the safety,
immunogenicity, and efficacy of its lead neoantigen cancer vaccine,
GEN-009, in a Phase 1/2a clinical trial. For more information,
please visit www.genocea.com.
Genocea Forward-Looking Statement This press
release includes forward-looking statements, including statements
relating to Genocea’s pre-clinical and clinical programs as well as
plans to partner its ATLAS technology platform, within the meaning
of the Private Securities Litigation Reform Act. Such
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statements. Genocea cautions that
these forward-looking statements are subject to numerous
assumptions, risks and uncertainties that change over time.
Applicable risks and uncertainties include those identified under
the heading "Risk Factors" included in Genocea's Annual Report on
Form 10-K for the year ended December 31, 2017 and any subsequent
SEC filings. These forward-looking statements speak only as of the
date of this press release and Genocea assumes no duty to update
forward-looking statements, except as may be required by law.
Contact: Jennifer LaVin
617-715-6687jennifer.lavin@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2024 to May 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From May 2023 to May 2024